Maryland State Retirement & Pension System Has $10.73 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Maryland State Retirement & Pension System lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,619 shares of the medical research company's stock after selling 1,406 shares during the quarter. Maryland State Retirement & Pension System's holdings in Thermo Fisher Scientific were worth $10,727,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. State Street Corp increased its stake in shares of Thermo Fisher Scientific by 0.8% during the third quarter. State Street Corp now owns 16,318,961 shares of the medical research company's stock valued at $10,100,655,000 after buying an additional 124,996 shares during the period. FMR LLC boosted its holdings in Thermo Fisher Scientific by 19.7% during the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company's stock worth $4,872,761,000 after buying an additional 1,294,453 shares in the last quarter. Geode Capital Management LLC raised its holdings in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after acquiring an additional 127,564 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Thermo Fisher Scientific by 5.7% in the third quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after purchasing an additional 262,062 shares in the last quarter. Finally, Amundi raised its holdings in shares of Thermo Fisher Scientific by 13.5% during the 4th quarter. Amundi now owns 2,860,847 shares of the medical research company's stock worth $1,556,689,000 after acquiring an additional 340,263 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently commented on TMO. Bank of America reduced their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last 90 days. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Trading Down 0.1 %

Thermo Fisher Scientific stock traded down $0.60 during trading on Friday, hitting $518.04. The company's stock had a trading volume of 2,159,706 shares, compared to its average volume of 1,540,546. The stock's fifty day moving average is $546.15 and its 200 day moving average is $555.91. The stock has a market capitalization of $195.44 billion, a price-to-earnings ratio of 31.34, a P/E/G ratio of 2.99 and a beta of 0.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.